{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:34:17Z","timestamp":1794278057487,"version":"4.9.0"},"reference-count":44,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med Insights Cardiol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hypertension affects over 1.3\u2009billion globally, many remain uncontrolled, and aldosterone synthase inhibitors (ASIs) are emerging as a treatment. This network meta-analysis compared the effectiveness and safety of ASI regimens in hypertensive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      PubMed, Cochrane Central, and ScienceDirect were searched till December 2025. We conducted a frequentist network meta-analysis using RStudio version 4.3.3 with the \u201cmeta\u201d and \u201cnetmeta\u201d packages.\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -scores were used for treatment ranking.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Ten randomized controlled trials were included in the analysis. Baxdrostat 1\u2009mg, 2\u2009mg, lorundrostat 100\u2009mg once daily, 12.5\u2009mg twice daily, 25\u2009mg twice daily, 50\u2009mg once daily, 50\u2009mg and escalation to 100\u2009mg, osilodrostat 0.25, 0.5, and 1.0\u2009mg once daily, vicadrostat 10, 20, and 3\u2009mg plus empagliflozin, and 20\u2009mg significantly reduced the systolic blood pressure (SBP), where the baxdrostat 2\u2009mg (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -score\u2009=\u20090.89) was ranked best. Lorundrostat 50\u2009mg once daily, Baxdrostat 1 and 2\u2009mg significantly reduced the diastolic blood pressure (DBP) with Lorundrostat 50\u2009mg once daily ranked best (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      -score\u2009=\u20090.84). Adverse events were increased with lorundrostat regimens, but serious adverse events were similar across regimens. Hyperkalemia was more frequent with Baxdrostat 1 and 2\u2009mg and all lorundrostat regimens. Symptomatic hypotension occurred mainly with lorundrostat 50\u2009mg daily.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The SBP and DBP were significantly reduced with the baxdrostat and lorundrostat regimens, although the risk of hyperkalemia increased. Adverse events were also higher in the lorundrostat regimens, whereas serious adverse events were comparable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/11795468261436180","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T15:04:47Z","timestamp":1776006287000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparing Efficacy and Safety of Different Aldosterone Synthase Inhibitors for Hypertension: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1177","volume":"20","author":[{"given":"Muhammad","family":"Hassan Waseem","sequence":"first","affiliation":[{"name":"Allama Iqbal Medical College, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain Ul","family":"Abideen","sequence":"additional","affiliation":[{"name":"King Edward Medical University, Lahore, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areeba","family":"Shoaib","sequence":"additional","affiliation":[{"name":"Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa Arshad Azam","family":"Raja","sequence":"additional","affiliation":[{"name":"Rawalpindi Medical University, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2085-8739","authenticated-orcid":false,"given":"Pawan Kumar","family":"Thada","sequence":"additional","affiliation":[{"name":"Sotang Primary Hospital, Solukhumbu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameer Haider","family":"Cheema","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"World Health Organization (WHO). Global Report on Hypertension: The Race Against a Silent Killer. World Health Organization; 2023:1-291. Accessed September 15 2025. https:\/\/www.who.int\/publications\/i\/item\/9789240081062"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0244-2"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003480"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac130"},{"issue":"5","key":"e_1_3_3_6_2","first-page":"431","article-title":"Impact of angiotensin receptor blockers (ARB) versus other antihypertensive medication on blood pressure in patients on dialysis: a meta-analysis","volume":"34","author":"Ds K","year":"2024","unstructured":"Ds K, MaryMary JJF, Mohan R, et al. Impact of angiotensin receptor blockers (ARB) versus other antihypertensive medication on blood pressure in patients on dialysis: a meta-analysis. Indian J Nephrol. 2024;34(5):431-441.","journal-title":"Indian J Nephrol"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037856"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003436"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-023-00891-1"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116521"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213169"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.16029"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102875"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.124.23962"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507109"},{"key":"e_1_3_3_16_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","journal-title":"BMJ"},{"key":"e_1_3_3_17_2","first-page":"1","author":"Higgins JPT","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. 1-694.","journal-title":"Cochrane Handbook for Systematic Reviews of Interventions"},{"key":"e_1_3_3_18_2","first-page":"366","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JAC","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:366.","journal-title":"BMJ"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00667.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15518"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.098467"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12051"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501440"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.9413"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02408-X"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1664810"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102875"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.5646\/ch.2025.31.e41"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2025-003535"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01070-4"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101918"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2276755"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00713-w"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07716"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000595"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac027"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2013.110"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000665"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70000"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.20376"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70094"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2025.09"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.057736"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac306"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-0294"}],"container-title":["Clinical Medicine Insights: Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795468261436180","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/11795468261436180","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/11795468261436180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:14:02Z","timestamp":1777389242000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/11795468261436180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":44,"alternative-id":["10.1177\/11795468261436180"],"URL":"https:\/\/doi.org\/10.1177\/11795468261436180","relation":{},"ISSN":["1179-5468","1179-5468"],"issn-type":[{"value":"1179-5468","type":"print"},{"value":"1179-5468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"11795468261436180"}}